MAPT and Alzheimer disease: With prior studies reporting a strong correlation between amyloid and tau PET imaging (Zammit et al., 2021; Tudorascu et al., 2020; Zammit et al., 2024; Pegueroles et al., 2023), the discrepancy between CSF amyloid measures and tau PET could be due to the fact that the former change as early as about 25 years prior to symptom onset, while changes in tau metabolism are further down the temporal sequence of AD pathology as a direct result of manifest amyloid plaques appearing roughly 10 years after CSF amyloid changes (Fortea et al., 2020).